Abbott Laboratories (ABT) Free Cash Flow (2009 - 2026)

Abbott Laboratories has disclosed Free Cash Flow across 18 years of filings, most recently posting $916.0 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $916.0 million, down 1.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 billion (up 10.83% YoY), and the FY2025 annual result was $7.4 billion, up 16.44% from the prior year.
• Free Cash Flow came in at $916.0 million for Q1 2026 at Abbott Laboratories, down from $2.6 billion in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.6 billion in Q4 2025 to a low of $627.0 million in Q1 2024.
• The 5-year median for Free Cash Flow is $1.7 billion (2022), against an average of $1.6 billion.
• Across the five-year window, Free Cash Flow tumbled 65.73% in 2023 and jumped 105.03% in 2024, its largest moves.
• Abbott Laboratories' Free Cash Flow stood at $1.7 billion in 2022, then surged by 33.04% to $2.3 billion in 2023, then dropped by 5.91% to $2.1 billion in 2024, then gained by 22.25% to $2.6 billion in 2025, then slumped by 65.12% to $916.0 million in 2026.
• The last three Free Cash Flow figures came in at $916.0 million (Q1 2026), $2.6 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.